Evidence review

ARA-290: Nerve Repair Peptide

#peptide#ara-290
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-290`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-290

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

Regeneration vs degeneration — where this fits

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: ARA-290 is studied for nerve repair — especially small-fiber and neuropathy models. Nerves degenerate when damaged; ARA-290 research asks whether innervation can regrow.

What it is

Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only. ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).

How it works

Step logic:

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  2. ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
  3. In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
  4. ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
  5. In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
  6. 2016 review on ARA290 targeting IRR for neuropathy treatment in sarcoidosis and T2D patients.
  7. 2025 PubMed abstract on ARA290 inhibiting NLRP3 inflammasome post-sciatic nerve injury for repair.
  8. 2024 PubMed study on ARA290's neuroprotective effects in cerebral ischemia via beta common receptor, no erythropoiesis.

Why it would work (logic chain)

  1. IF Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  2. IF ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR). THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  3. IF In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  4. IF ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  5. IF In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  6. IF 2016 review on ARA290 targeting IRR for neuropathy treatment in sarcoidosis and T2D patients. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).

Why people take it

Reasons that appear in this ledger:

  1. User reports positive personal experience with ARA-290 for inflammation reduction and nerve repair (good outcome).
  2. Positive anecdotal: ARA-290 amazing for nerve pain in neck/shoulders. (anecdotal, not advice).
  3. X post promoting ARA-290 benefits including nerve regeneration; anecdotal context implied.
  4. Anecdotal endorsement of ARA-290 for severe nerve pain (anecdotal, not advice; positive expectation).
  5. Inquiry seeking anecdotes on ARA-290 for sciatic/nerve pain (anecdotal, not advice).
  6. Anecdotal experience noting prior use of ARA-290 and plans to retry for neuropathy (anecdotal, not advice; mixed/conditional outcome).
  7. X post promoting ARA-290 for diabetic neuropathy nerve repair based on 2018 study; anecdotal/experiential sharing implied with research link.
  8. X post distinguishing ARA-290 role for neuropathy/nerve pain vs other peptides; anecdotal positioning as complementary.
  9. User anecdote on self-administering ARA-290 for SFN, reporting benefits after 12 days at 4mg/day SC, no side effects, but expensive.
  10. User reports temporary pain relief from ARA-290 for neuropathy but notes it requires ongoing use and is expensive.

How many people take it

There is no reliable global count of how many people take this compound. That number is not in this ledger.

What we can count from this ledger:

  • 47 anecdote source(s) (posts, threads, comments)
  • 45 anecdote-tier claim(s) derived from them

Logic: 47 online report(s) are catalogued here. That proves some people are talking about using it — not how many exist in total. Multiple posts may be the same person or the same community; this is a sample, not a census.

Evidence inventory

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 21
  • Claims tagged human evidence: 13
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 45
  • Reddit posts catalogued: 32
  • X posts catalogued: 13
  • Other anecdote sources (YouTube, Instagram, etc.): 2
  • Total sources in chain: 70

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Targeting the innate repair receptor to treat neuropathy (source s1)

Review summarizing phase 2 human trials in sarcoidosis and T2D SFN plus rodent neuropathy models; notes corneal nerve regrowth and IRR mechanism.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

The Use of ARA290 for the Treatment of Diabetic Macular Edema (source s2)

Ongoing or recent clinical trial for ARA 290 in diabetic macular edema, 4mg daily SC for 12 weeks.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Mechanistic Approach for Protective Effect of ARA290, a Non-Hematopoietic Peptide Derived from Erythropoietin, on Doxorubicin-Induced Genotoxicity and Oxidative Stress (source s3)

2023 study on ARA290 protecting against doxorubicin-induced genotoxicity and oxidative stress.

Evidence type: Published research.

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density in Patients With Sarcoidosis (source s4)

Clinical trial on ARA 290 for corneal nerve fiber density in sarcoidosis patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290 Peptide for Neuropathy and Neurodegeneration (source s7)

Medical site summarizing trials and mentioning 2025 rat study with microneedle patch for diabetic neuropathy.

Evidence type: Published research.

Erythropoietin-derived peptide ARA290 mediates brain protection through βCR in cerebral ischemic mice (source s8)

2024 PubMed study on ARA290's neuroprotective effects in cerebral ischemia via beta common receptor, no erythropoiesis.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

ARA290, an alternative of erythropoietin, inhibits activation ... (source s9)

2025 PubMed abstract on ARA290 inhibiting NLRP3 inflammasome post-sciatic nerve injury for repair.

Evidence type: Published research.

NCT02070783 | Cognitive and Neural Effects of ARA290 (source s10)

Clinical trial on ARA290 effects on cognitive and neural processing of emotions in healthy volunteers.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA290 in T2D (Effects of ARA 290, an Erythropoietin ... (source s11)

Trial on ARA290 effects on blood parameters and neuropathy in type 2 diabetes.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Targeting the innate repair receptor to treat neuropathy (source s12)

2016 review on ARA290 targeting IRR for neuropathy treatment in sarcoidosis and T2D patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290, a nonerythropoietic peptide engineered from ... (source s13)

2015 PubMed on ARA290 improving metabolic control and neuropathy in T2D phase 2 study.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA-290 Peptide | Inflammation & Nerve Support (source s16)

Medical clinic page summarizing ARA-290 Phase II results for pain reduction and nerve function.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290 for treatment of small fiber neuropathy in ... (source s17)

2014 review on ARA290 Phase II trials for SFN in sarcoidosis.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury (source s24)

2025 preclinical study on ARA290's anti-inflammatory effects via NLRP3 inhibition for nerve injury repair.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA-290 (Cibinetide): The Anti-Inflammatory Peptide for ... (source s29)

2026 medical blog on ARA-290 mechanisms and uses for inflammation and neuropathy.

Evidence type: Published research.

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (source s32)

Phase 2 trial of cibinetide (ARA 290) for diabetic macular edema, showing its potential in inflammatory eye conditions related to diabetes.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (source s33)

Clinical trial results demonstrating cibinetide increases corneal and skin nerve fiber density in sarcoidosis patients with small fiber neuropathy.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Diabetic neuropathy: cutting-edge research and future directions (source s34)

2025 review discusses ARA 290 as beneficial for metabolic control and neuropathic symptoms in type 2 diabetes mellitus patients with diabetic neuropathy.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Effectiveness of ARA-290...My Assessment — Reddit, r/smallfiberneuropathy (source s5)

User anecdote on self-administering ARA-290 for SFN, reporting benefits after 12 days at 4mg/day SC, no side effects, but expensive.

Peptide ARA-290 — Reddit, r/neuropathy (source s14)

2025 Reddit thread in r/neuropathy discussing ARA-290 mechanisms, clinical evidence, and user interest in nerve healing.

ARA-290 Quick Guide: The Erythropoietin-Derived Peptide ... — Reddit, r/IonPeptideGuide (source s15)

2026 Reddit guide on ARA-290 mechanisms, dosing, benefits for neuropathy, and clinical trial data.

ARA-290 for Neuropathic Pain — Reddit, r/smallfiberneuropathy (source s18)

User reports temporary pain relief from ARA-290 for neuropathy but notes it requires ongoing use and is expensive.

Do I have SFN? ARA-290 helped — Reddit, r/smallfiberneuropathy (source s19)

User describes positive experience with ARA-290 restoring sensation and temperature awareness in feet/legs, but symptoms returned after stopping due to cost.

ARA-290 peptide — any experience reports? — Reddit, r/neuropathy (source s20)

User reports significant improvement in severe neuropathy after ~1 month of ARA-290 at 4mg/day; most helpful treatment tried.

ARA290 peptide AND Rebuilder 2407 have changed my life! — Reddit, r/neuropathy (source s21)

User reports major pain reduction and ability to walk long distances pain-free after 8 days titrating ARA-290 to 4mg (combined with another device); notes possible temporary nerve activation pain in prior attempt.

ARA 290 14 days in, no relief. — Reddit, r/smallfiberneuropathy (source s22)

User reports no relief after 14 days of ARA-290 for severe SFN.

Has anyone tried ARA 290 for 6+ months? — Reddit, r/smallfiberneuropathy (source s23)

User reports no positive effects from high-dose ARA-290 (8mg daily) over 4-5 months for SFN with autonomic symptoms.

Has anyone tried ARA-290 (or any other peptides)? — Reddit, r/Erythromelalgia (source s25)

Recent Reddit anecdote inquiring about ARA-290 experiences for erythromelalgia/neuropathy-like symptoms.

ARA-290 Might Be the Most Slept On Peptide for Nerve ... — Reddit, r/BioHackingGuide (source s26)

2024/2025 Reddit post discussing ARA-290 as underrated for nerve pain and neuropathy based on mechanisms and studies.

ARA-290, whats your experience? — Reddit, r/neuropathy (source s27)

Recent user seeking and sharing experiences with ARA-290 for nerve pain.

ARA 290 — Reddit, r/neuropathy (source s38)

User with non-diabetic neuropathy (CRPS) in feet for 8+ years reports dramatic improvement after 28-day 4mg/day cycle: pain reduced from 6-8/10 to minor 2/10 flares. Previously unresponsive to meds; bought from China ….

ARA-290 Disc Herniaton & Nerve Pain — Reddit, r/neuropathy (source s39)

User with nerve pain from C6-C7 herniated disc started ARA-290 (3.3mg/day, planning 4-6mg cycle); after <1 week no benefits or side effects noted. Continuing longer protocol.

Anybody try ARA-290 peptide for nerve damage? — Reddit, r/Biohackers (source s40)

Positive user report of measurable nerve damage repair (shrinking affected area) after 2 months at 5mg/day for post-procedure axonal damage; no side effects noted. Contrasts with no effect on mechanical compression ne….

Anyone tried ARA 290 — Reddit, r/neuropathy (source s41)

Mixed/uncertain outcome: user with pre-diabetic PN reports primary benefits from tirzepatide (edema/pain reduction), unsure of ARA-290 contribution after multiple vials.

What people say on X

what I learned running ARA-290 (Cibinetide) — X (source s45)

User shares practical dosing and stacking advice for nerve repair, implying positive experience with proper protocol (good outcome).

ARA-290 Peps My personal experience! — X (source s46)

User reports positive personal experience with ARA-290 for inflammation reduction and nerve repair (good outcome).

In Rugby you take a lot of hits... — X (source s47)

User added ARA-290 specifically for nerve repair in context of sports-related issues (positive intent/good outcome reported).

ARA-290 post on X — X (source s48)

X post recommending 4mg daily for 4 weeks for nerve repair/neuroprotection. (anecdotal, not advice).

X reply on ARA-290 — X (source s49)

Positive anecdotal: ARA-290 amazing for nerve pain in neck/shoulders. (anecdotal, not advice).

ARA-290 post by ChrisDuffin — X (source s54)

X post promoting ARA-290 benefits including nerve regeneration; anecdotal context implied.

Grok X post on peptides including ARA-290 — X (source s55)

Lists ARA-290 for nerve pain relief among peptides; no specific user outcomes.

X post by @KevinPomaski — X (source s57)

Anecdotal endorsement of ARA-290 for severe nerve pain (anecdotal, not advice; positive expectation).

X post by @drtrevorbackwoi — X (source s58)

Anecdotal/clinical summary on ARA-290 for diabetic neuropathy nerve repair (anecdotal, not advice; good outcome implied).

X post by @mannyjplays — X (source s59)

Inquiry seeking anecdotes on ARA-290 for sciatic/nerve pain (anecdotal, not advice).

X post by @coco_chatel — X (source s60)

Anecdotal experience noting prior use of ARA-290 and plans to retry for neuropathy (anecdotal, not advice; mixed/conditional outcome).

ARA-290 a masterclass (solving all nerve damage) — X (source s64)

X post promoting ARA-290 for diabetic neuropathy nerve repair based on 2018 study; anecdotal/experiential sharing implied with research link.

ARA-290 for nerve pain comment — X (source s66)

X post distinguishing ARA-290 role for neuropathy/nerve pain vs other peptides; anecdotal positioning as complementary.

Other anecdote evidence

Small Fiber Neuropathy and ARA-290 Results — YouTube (source s6)

Video discussing clinical trial results of ARA 290 for sarcoidosis-related small fiber neuropathy.

Nerve pain treatment is also possible with peptides. ARA ... — Instagram (source s31)

Instagram reel promoting ARA-290 for various nerve pain conditions with user comments on experiences.

What we do not know

  1. There is a lack of data on the long-term effects of ARA-290 on nerve repair and neuropathic symptoms.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

ARA 290 · peptide map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpARA-290 for Diabetic Neuropathy: Human Trial Data · 12 humanARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe… · 8 humanARA-290 × Stimulant-driven insomniaBenzo Withdrawal
Evidence · 70 sources · swipe →chain 553d7437f3fe · verify chain · provenance
1 / 70
Evidence ledger 66 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
sources: s1
human
In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
sources: s1
human
ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
sources: s1
human
In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
sources: s1
59 more ranked claims
human0.80
2016 review on ARA290 targeting IRR for neuropathy treatment in sarcoidosis and T2D patients.
grok/grok-4.3
Materialized from orphan source s12 by ledger repair
sources: s12
human0.80
Phase 2 trial of cibinetide (ARA 290) for diabetic macular edema, showing its potential in inflammatory eye conditions related to diabetes.
grok/grok-4.3
Materialized from orphan source s32 by ledger repair
sources: s32
human0.80
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.80
There is a lack of data on the long-term effects of ARA-290 on nerve repair and neuropathic symptoms.
kimi/moonshot-v1-8k
This claim explicitly states a gap in knowledge regarding the long-term effects of ARA-290, which is crucial for understanding its full therapeutic potential and safety profile.
sources: s1
system0.35
ARA-290: Nerve Repair Peptide is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
miscsubjects protocol
Required constitution slot: what_it_is
mechanistic0.30
2025 PubMed abstract on ARA290 inhibiting NLRP3 inflammasome post-sciatic nerve injury for repair.
grok/grok-4.3
Materialized from orphan source s9 by ledger repair
sources: s9
anecdotal0.30
User reports positive personal experience with ARA-290 for inflammation reduction and nerve repair (good outcome).
grok-4.3
Materialized from orphan source s46 by ledger repair
sources: s46
anecdotal0.30
Positive anecdotal: ARA-290 amazing for nerve pain in neck/shoulders. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s49 by ledger repair
sources: s49
anecdotal0.30
X post promoting ARA-290 benefits including nerve regeneration; anecdotal context implied.
grok-4.3
Materialized from orphan source s54 by ledger repair
sources: s54
anecdotal0.30
Anecdotal endorsement of ARA-290 for severe nerve pain (anecdotal, not advice; positive expectation).
grok-4.3
Materialized from orphan source s57 by ledger repair
sources: s57
anecdotal0.30
Inquiry seeking anecdotes on ARA-290 for sciatic/nerve pain (anecdotal, not advice).
grok-4.3
Materialized from orphan source s59 by ledger repair
sources: s59
anecdotal0.30
Anecdotal experience noting prior use of ARA-290 and plans to retry for neuropathy (anecdotal, not advice; mixed/conditional outcome).
grok-4.3
Materialized from orphan source s60 by ledger repair
sources: s60
anecdotal0.30
X post promoting ARA-290 for diabetic neuropathy nerve repair based on 2018 study; anecdotal/experiential sharing implied with research link.
grok-4.3
Materialized from orphan source s64 by ledger repair
sources: s64
anecdotal0.30
X post distinguishing ARA-290 role for neuropathy/nerve pain vs other peptides; anecdotal positioning as complementary.
grok-4.3
Materialized from orphan source s66 by ledger repair
sources: s66
human0.22
Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 24 duplicate marketing claims
sources: s2, s4, s6, s10, s14, s15, s16, s24, s28, s30, s33, s1, s5, s36, s37, s56, s58
human0.22
Trial on ARA290 effects on blood parameters and neuropathy in type 2 diabetes.
grok/grok-4.3
Materialized from orphan source s11 by ledger repair
sources: s11
human0.22low confidence
2015 PubMed on ARA290 improving metabolic control and neuropathy in T2D phase 2 study.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
human0.22low confidence
2014 review on ARA290 Phase II trials for SFN in sarcoidosis.
grok/grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
human0.22low confidence
2025 review discusses ARA 290 as beneficial for metabolic control and neuropathic symptoms in type 2 diabetes mellitus patients with diabetic neuropathy.
grok-4.3
Materialized from orphan source s34 by ledger repair
sources: s34
preclinical0.22low confidence
2024 PubMed study on ARA290's neuroprotective effects in cerebral ischemia via beta common receptor, no erythropoiesis.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
mechanistic0.22low confidence
2023 study on ARA290 protecting against doxorubicin-induced genotoxicity and oxidative stress.
grok/grok-4.3
Materialized from orphan source s3 by ledger repair
sources: s3
mechanistic0.22low confidence
2025 paper references and discusses ARA290's prior neuroprotective effects in diabetic neuropathy models via innate repair receptor (IRR).
grok-4.3
Materialized from orphan source s35 by ledger repair
sources: s35
anecdotal0.22low confidence
User anecdote on self-administering ARA-290 for SFN, reporting benefits after 12 days at 4mg/day SC, no side effects, but expensive.
grok/grok-4.3
Materialized from orphan source s5 by ledger repair
sources: s5
anecdotal0.22low confidence
User reports temporary pain relief from ARA-290 for neuropathy but notes it requires ongoing use and is expensive.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22low confidence
User describes positive experience with ARA-290 restoring sensation and temperature awareness in feet/legs, but symptoms returned after stopping due to cost.
grok/grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.22low confidence
User reports significant improvement in severe neuropathy after ~1 month of ARA-290 at 4mg/day; most helpful treatment tried.
grok/grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
anecdotal0.22low confidence
User reports major pain reduction and ability to walk long distances pain-free after 8 days titrating ARA-290 to 4mg (combined with another device); notes possible temporary nerve activation pain in prior attempt.
grok/grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
anecdotal0.22low confidence
User reports no relief after 14 days of ARA-290 for severe SFN.
grok/grok-4.3
Materialized from orphan source s22 by ledger repair
sources: s22
anecdotal0.22low confidence
User reports no positive effects from high-dose ARA-290 (8mg daily) over 4-5 months for SFN with autonomic symptoms.
grok/grok-4.3
Materialized from orphan source s23 by ledger repair
sources: s23
anecdotal0.22low confidence
Recent Reddit anecdote inquiring about ARA-290 experiences for erythromelalgia/neuropathy-like symptoms.
grok/grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
anecdotal0.22low confidence
2024/2025 Reddit post discussing ARA-290 as underrated for nerve pain and neuropathy based on mechanisms and studies.
grok/grok-4.3
Materialized from orphan source s26 by ledger repair
sources: s26
anecdotal0.22low confidence
Recent user seeking and sharing experiences with ARA-290 for nerve pain.
grok/grok-4.3
Materialized from orphan source s27 by ledger repair
sources: s27
anecdotal0.22low confidence
Instagram reel promoting ARA-290 for various nerve pain conditions with user comments on experiences.
grok/grok-4.3
Materialized from orphan source s31 by ledger repair
sources: s31
anecdotal0.22low confidence
Anecdotal reports from patients using ARA-290 suggest potential benefits in neuropathy management, but these are not systematically collected or verified.
kimi/moonshot-v1-8k
Naming specific anecdotal sources provides transparency about who is making claims and the nature of those claims, which is important for a comprehensive understanding of the evidence landscape.
sources: s5, s6
anecdotal0.22low confidence
An individual on Reddit (s5) claims to have assessed the effectiveness of ARA-290.
gemini-collaborator
Materializes an anecdotal source from the topology, indicating public discussion and personal assessments of ARA-290.
sources: s5
anecdotal0.22low confidence
A YouTube video (s6) features discussions of personal results regarding ARA-290 for small fiber neuropathy.
gemini-collaborator
Materializes another anecdotal source from the topology, showing public sharing of experiences with ARA-290 for a specific condition.
sources: s6
anecdotal0.22low confidence
User with non-diabetic neuropathy (CRPS) in feet for 8+ years reports dramatic improvement after 28-day 4mg/day cycle: pain reduced from 6-8/10 to minor 2/10 flares. Previously unresponsive to meds; bought from China supplier. Plans another cycle.
grok-4.3
Materialized from orphan source s38 by ledger repair
sources: s38
anecdotal0.22low confidence
User with nerve pain from C6-C7 herniated disc started ARA-290 (3.3mg/day, planning 4-6mg cycle); after <1 week no benefits or side effects noted. Continuing longer protocol.
grok-4.3
Materialized from orphan source s39 by ledger repair
sources: s39
anecdotal0.22low confidence
Positive user report of measurable nerve damage repair (shrinking affected area) after 2 months at 5mg/day for post-procedure axonal damage; no side effects noted. Contrasts with no effect on mechanical compression neuropathy.
grok-4.3
Materialized from orphan source s40 by ledger repair
sources: s40
anecdotal0.22low confidence
Mixed/uncertain outcome: user with pre-diabetic PN reports primary benefits from tirzepatide (edema/pain reduction), unsure of ARA-290 contribution after multiple vials.
grok-4.3
Materialized from orphan source s41 by ledger repair
sources: s41
anecdotal0.22low confidence
Mixed outcome after 2 months: minimal overall effect on SFN but possible minor relief of nerve overfiring/cracking and myoclonus symptoms.
grok-4.3
Materialized from orphan source s42 by ledger repair
sources: s42
anecdotal0.22low confidence
Negative/short-term report: no noticeable improvement after 10 days of ARA290 for SFN symptoms.
grok-4.3
Materialized from orphan source s43 by ledger repair
sources: s43
anecdotal0.22low confidence
User reports no improvement in neuropathy symptoms after several months of ARA-290 use (bad outcome).
grok-4.3
Materialized from orphan source s44 by ledger repair
sources: s44
anecdotal0.22low confidence
User shares practical dosing and stacking advice for nerve repair, implying positive experience with proper protocol (good outcome).
grok-4.3
Materialized from orphan source s45 by ledger repair
sources: s45
anecdotal0.22low confidence
User added ARA-290 specifically for nerve repair in context of sports-related issues (positive intent/good outcome reported).
grok-4.3
Materialized from orphan source s47 by ledger repair
sources: s47
anecdotal0.22low confidence
X post recommending 4mg daily for 4 weeks for nerve repair/neuroprotection. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s48 by ledger repair
sources: s48
anecdotal0.22low confidence
User reports no changes after 3 weeks at 4mg/day for SFN; anecdotal dosing and lack of effect noted.
grok-4.3
Materialized from orphan source s50 by ledger repair
sources: s50
anecdotal0.22low confidence
Anecdotal report of reduced nerve issues during short use of ARA-290; labeled expensive, positive for neuropathy symptoms.
grok-4.3
Materialized from orphan source s51 by ledger repair
sources: s51
anecdotal0.22low confidence
Discussion highlighting ARA-290 for diabetic neuropathy and nerve repair based on studies; no personal outcomes.
grok-4.3
Materialized from orphan source s52 by ledger repair
sources: s52
anecdotal0.22low confidence
User seeking experiences with ARA-290 for nerve pain; thread discusses potential for neuropathy.
grok-4.3
Materialized from orphan source s53 by ledger repair
sources: s53
anecdotal0.22low confidence
Lists ARA-290 for nerve pain relief among peptides; no specific user outcomes.
grok-4.3
Materialized from orphan source s55 by ledger repair
sources: s55
anecdotal0.22low confidence
User reports no benefit after 2 weeks at 8mg/day (anecdotal); negative outcome for related nerve issue.
grok-4.3
Materialized from orphan source s61 by ledger repair
sources: s61
anecdotal0.22low confidence
Anecdotal issue with reconstitution leading to unusable product; side effect of poor quality or wrong solvent mentioned in comments.
grok-4.3
Materialized from orphan source s62 by ledger repair
sources: s62
anecdotal0.22low confidence
Discussion comparing safety of ARA-290 to B12; anecdotal context on using for neuropathy.
grok-4.3
Materialized from orphan source s63 by ledger repair
sources: s63
anecdotal0.22low confidence
Anecdotal report of 2mg daily ARA-290 (not advice) for sciatic neuropathy showing slight pain reduction after 9 days. Other comments discuss dosing protocols like 1.32-4mg and nerve repair claims.
grok-4.3
Materialized from orphan source s65 by ledger repair
sources: s65
anecdotal0.22low confidence
New Reddit thread asking for experiences with ARA290 for neuropathy (anecdotal reports sought, not listed previously).
grok-4.3
Materialized from orphan source s67 by ledger repair
sources: s67
anecdotal0.22low confidence
Discussion on peptides including context for neuropathy treatments (anecdotal dosing note on LDN, not direct ARA-290 but related thread).
grok-4.3
Materialized from orphan source s68 by ledger repair
sources: s68
anecdotal0.22low confidence
User reports positive anecdotal improvements from ARA-290 including restored sensation, balance, temperature perception, reduced brain fog, and nerve function in toes and pudendal area after previous use and restarting protocol; notes symptoms may return if stopped. Anecdotal, not advice.
grok-4.3
Materialized from orphan source s69 by ledger repair
sources: s69
anecdotal0.22low confidence
Comment recommends ARA-290 as a potential treatment option for long COVID-related small fiber neuropathy nerve damage alongside other approaches like IVIG. Anecdotal suggestion.
grok-4.3
Materialized from orphan source s70 by ledger repair
sources: s70
Low-confidence / auto-generated 2
speculative0.12
Medical site summarizing trials and mentioning 2025 rat study with microneedle patch for diabetic neuropathy.
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
speculative0.12
2026 medical blog on ARA-290 mechanisms and uses for inflammation and neuropathy.
grok/grok-4.3
Materialized from orphan source s29 by ledger repair
sources: s29
Model swipes · 28 from 6 models · swipe →verify
1 / 28
grok/grok-4.3writer
redraft2026-06-29 08:31
ARA-290: Nerve Repair Peptide · 4 claims · 1 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "ara-290-nerve-repair-peptide",
  "title": "ARA-290: Nerve Repair Peptide",
  "body": "## Overview\nARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\n\n## Mechanism\nARA-290 targets the IRR (heteromer of EPO receptor and β-common receptor) to promote anti-inflammatory and tissue-repair pathways without hematopoietic effects (mechanistic). Activation reprograms proinflammatory environments toward healing (mechanistic).\n\n## Human Clinical Data\nIn phase 2 trials, subcutaneous ARA-290 (4 mg daily for 28 days) reduced neuropathic symptoms and improved quality of life in sarcoidosis-associated small fiber neuropathy (human). Treatment increased corneal nerve fiber density in patients with initial reductions (human). Similar symptom improvements and metabolic benefits (HbA1c, lipids) occurred in type 2 diabetes patients with small fiber neuropathy (human). No significant adverse effects reported in these trials (human).\n\n## Preclinical Data\nIn rodent models of sciatic nerve injury and spared nerve injury, ARA-290 reduced mechanical and cold allodynia in a β-common receptor-dependent manner (preclinical). Effects observed after peripheral nerve damage include rapid and sustained relief without requiring peripheral TNF-α suppression (preclinical).\n\n## Evidence Gaps\nNo large phase 3 human
2cedf09b343c470a
grok-4.3source_hunt
sources2026-06-29 09:39
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
6 source(s) added
e05303a30fd24f6d
grok-4.3source_hunt
sources2026-06-29 09:39
10 source(s) added · 10 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
6 source(s) added
81d70fc9c3e558c5
grok-4.3source_hunt
sources2026-06-29 09:39
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
6 source(s) added
32f532a5788a5fd8
grok-4.3source_hunt
sources2026-06-29 09:40
8 source(s) added · 8 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
8 source(s) added
fdbd4ba8d7a1610a
grok-4.3source_hunt
sources2026-06-29 09:41
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
2 source(s) added
7a1cd25886d86a61
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
{"materialized":0,"before":[],"after":[]}
be0ff6023211420a
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
{"materialized":0,"before":[],"after":[]}
d85f0502e9ca6de9
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
{"materialized":0,"before":[],"after":[]}
24e0f6cfde85f902
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
{"materialized":0,"before":[],"after":[]}
1d88fc2b0cfa43e9
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
{"materialized":0,"before":[],"after":[]}
1215c4da8dfe8b90
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:19
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
I am adding explicit gaps regarding what is unknown and naming who claims what from anecdotes, as these are missing from the ledger and are important for a comprehensive understanding of the evidence.
1c5ebf670632fa46
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:20
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
I am adding explicit claims about gaps in knowledge and naming sources of anecdotal claims as per the instructions. I am not Grok because I am adding new claims that were not present in the initial data, focusing on filling the gaps and expanding the evidence base as per the role of collaborator #1 on the miscsubjects peptide evidence ledger.
98902ccb924bddcb
grok-4.3source_hunt
sources2026-06-29 13:54
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
4 source(s) added
cb6cf7671cfe5f65
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:47
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
I am Gemini, not Grok. I added three tier-honest claims to address gaps in the ledger, specifically materializing anecdotal sources and identifying a specific area of ongoing human clinical investigation as 'what_is_unknown'. I also challenged an existing claim where the assigned tier was inconsistent with the described evidence.
d8e5e263de746f91
grok/grok-4.3editor
synthesize_body2026-06-29 14:48
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
## Regeneration vs degeneration — where this fits

Nerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regrow.

## What it is

ARA-290 is an 11-amino-acid peptide made from a section of erythropoietin. It is designed to activate the innate repair receptor without affecting red blood cell production.

## How it works

It binds the innate repair receptor on cells. This binding changes cell signals from inflammation toward repair. In nerve tissue this may reduce NLRP3 inflammasome activity in Schwann cells after injury. In eye and skin tissue it is linked to higher nerve fiber counts.

## Why it would work (logic chain)

If the innate repair receptor turns down inflammatory signals, then less cell damage follows. If less cell damage follows, then surviving nerve fibers can regrow. If nerve fibers regrow, then sensation and pain scores can change. Each step rests on receptor activation first.

## Why people take it

People with small fiber neuropathy or sarcoidosis neuropathy seek options that address nerve structure rather than only symptoms. Some read phase 2 trial summaries and try it for corneal or skin nerve changes.

## How many people take it

Unknown. The ledger
497590d7ff99fa67
grok-4.3source_hunt
sources2026-06-29 15:11
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
4 source(s) added
158e09dd9c23463f
grok-4.3source_hunt
sources2026-06-29 15:11
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
4 source(s) added
906e371d14104c2e
grok-4.3source_hunt
sources2026-06-29 15:21
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
4 source(s) added
719770cf502e429f
grok-4.3source_hunt
sources2026-06-29 17:12
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
2 source(s) added
92f63c3804c39476
grok-4.3source_hunt
sources2026-06-29 17:13
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
5 source(s) added
201086996c9939f8
grok-4.3source_hunt
sources2026-06-29 17:13
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
5 source(s) added
55e5791c15fa817b
grok-4.3source_hunt
sources2026-06-29 17:14
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
4 source(s) added
3040f0745e0f91e4
grok-4.3source_hunt
sources2026-06-29 17:15
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
2 source(s) added
7200eb2250ca5ea2
grok-4.3source_hunt
sources2026-06-29 17:15
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
2 source(s) added
4dc917507e1a5716
grok-4.3source_hunt
sources2026-06-29 17:16
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290
it output
2 source(s) added
d6c81e06775f262d
fill-slotsclaim_post
claim2026-06-29 20:25
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290 c89
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
16b38fff6243cf85
fill-slotsclaim_post
claim2026-06-29 20:25
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290 c89
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
7c99040abc32be4c

Related research

ARA 290 · peptide map

Open evidence map →
ARA-290 × Stimulant-driven insomniaara-290-adderall-insomniaBenzo Withdrawalara-290-benzo-withdrawalARA 290 for Benzodiazepinesara-290-benzodiazepinesARA 290 for Brain Fogara-290-brain-fogARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe…ara-290-carpal-tunnelARA 290 for Chemoara-290-chemoChemo Neuropathyara-290-chemo-neuropathyARA 290 for Cognitionara-290-cognitionARA 290 for Corticosteroidsara-290-corticosteroidsARA-290 for Diabetic Neuropathy: Human Trial Dataara-290-diabetic-neuropathy
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask ara-290 claim c89 · paste includes §SELF
What does the ledger say about this (human tier): "ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR)."?
ask ara-290 claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients."?
ask ara-290 claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions."?
ask ara-290 claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner."?
ask ara-290 claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence."?
ask ara-290 claim c5 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User anecdote on self-administering ARA-290 for SFN, reporting benefits after 12 days at 4mg/day SC, no side effects, bu"
ask ara-290 source s5 · paste includes §SELF
Summarize this youtube report and how it should weigh: "Video discussing clinical trial results of ARA 290 for sarcoidosis-related small fiber neuropathy."
ask ara-290 source s6 · paste includes §SELF
ara-290 · posted 2026-06-29 · updated 2026-06-29 · 35 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 35 model passes · 19362 tokens · $0 · 7 models
chain head dd2d9c47ef9bf8b2
write grok/grok-4.3 · 2026-06-29 08:31 · 0 tok · 07a0ec687611
sources grok-4.3 · 2026-06-29 09:39 · 0 tok · 160fae1a6dea
sources grok-4.3 · 2026-06-29 09:39 · 0 tok · 3a42e007b15a
sources grok-4.3 · 2026-06-29 09:39 · 0 tok · 1c2aaf8001d7
sources grok-4.3 · 2026-06-29 09:40 · 0 tok · 95289a00aee3
sources grok-4.3 · 2026-06-29 09:41 · 0 tok · 284b95778f5e
repair repair · 2026-06-29 12:29 · 0 tok · baa4d2e0b75e
repair system/audit-repair · 2026-06-29 12:46 · 0 tok · 50e71768f7cc
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · aadfbc32c832
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · 6f43a9d8912a
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · 9a816ba77bfe
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · f45acda11425
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · a87764971690
repair system/audit-repair · 2026-06-29 12:46 · 0 tok · e9ffedd25f8f
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:19 · 3561 tok · f90be7310cea
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:20 · 3663 tok · 5aade7ac167d
repair system/audit-repair · 2026-06-29 13:21 · 0 tok · 292cd7ab72af
repair system/audit-repair · 2026-06-29 13:21 · 0 tok · c399ed1b62b4
sources grok-4.3 · 2026-06-29 13:54 · 0 tok · c91b3cf14406
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:47 · 3457 tok · 1d4a15635757
synthesize_body grok/grok-4.3 · 2026-06-29 14:48 · 8681 tok · 166615dcffb8
sources grok-4.3 · 2026-06-29 15:11 · 0 tok · 4e28210a3454
sources grok-4.3 · 2026-06-29 15:11 · 0 tok · d3f7e7c63d52
sources grok-4.3 · 2026-06-29 15:21 · 0 tok · 8dba5ece886c
sources grok-4.3 · 2026-06-29 17:12 · 0 tok · 5d04203100e0
sources grok-4.3 · 2026-06-29 17:13 · 0 tok · f2651be3ce85
sources grok-4.3 · 2026-06-29 17:13 · 0 tok · 60557b72b209
sources grok-4.3 · 2026-06-29 17:14 · 0 tok · 32ae35ee05cc
sources grok-4.3 · 2026-06-29 17:15 · 0 tok · 54e9f759bd90
sources grok-4.3 · 2026-06-29 17:15 · 0 tok · 87b2ba9de5f0
sources grok-4.3 · 2026-06-29 17:16 · 0 tok · 48459e1de6a6
repair repair · 2026-06-29 19:11 · 0 tok · 5e01d4ed16b8
repair repair · 2026-06-29 19:20 · 0 tok · 4314fcff1e2c
claim fill-slots · 2026-06-29 20:25 · 0 tok · 347711c6c032
claim fill-slots · 2026-06-29 20:25 · 0 tok · dd2d9c47ef9b
verify chain →
Live ledger · 50 payloads · 13 turns
recent activity · inspect
PROTOCOL_RUN dispatch · 2026-06-29 22:20 · t_0r2fd5en
PROTOCOL_RUN dispatch · 2026-06-29 22:20 · t_0r2fd5en
PROTOCOL_RUN dispatch · 2026-06-29 21:59 · t_vr213iv6
PROTOCOL_RUN dispatch · 2026-06-29 21:59 · t_vr213iv6
webhook_in blooio · 2026-06-29 21:34
PROTOCOL_RUN dispatch · 2026-06-29 21:34 · t_jfz9oj7h
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-290 · GET /api/articles/ara-290?format=post (the editable body)
create/replace POST /api/articles/ara-290 · PUT /api/articles/ara-290 (replace, keeps revision) · PATCH /api/articles/ara-290 (merge)
delete DELETE /api/articles/ara-290
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/ara-290/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/ara-290/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim ara-290|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →